TP-021 (BCL6-IN-8c) is a potent and orally active B-cell lymphoma 6 (BCL6)-corepressor interaction inhibitor with an IC 50 of 0.10 µM in cell-free enzyme-linked immunosorbent assay In Vitro TP-021 (BCL6-IN-8c, Compound 8c) also exhibits good cellular PPI inhibitory activity in the submicromolar range (M2H IC 50 = 0.72 µM). TP-021 (BCL6-IN-8c) does not exhibit significant cytotoxicity even at 30 µM. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo The pharmacokinetic profile of TP-021 (BCL6-IN-8c, Compound 8c) is evaluated by a mouse cassette-dosing study (0.1 mg/kg iv; 1 mg/kg po). TP-021 (BCL6-IN-8c) exhibits a good pharmacokinetic profile (C max = 233 ng/mL, T max = 2 hours, MRT = 3.3 h, AUC = 1.27 mg•h/mL, F (oral bioavailability) = 79.9%) . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:IC50: 0.10 µM (BCL6-corepressor interaction)
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
TP-021
CAS number：2130878-25-8 molecular formula：C20H20ClN3O5
overview
compound introduction
Specs
| Chinese alias | - | ||
| English alias | - | ||
| CAS number | 2130878-25-8 | molecular formula | C20H20ClN3O5 |
| molecular weight | 417.84 g/mol | Exact mass | ≥99% |
| PSA | - | logp | - |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
